Controlled flow-through dissolution methodology: A high-performance system

Pharmaceutical Development and Technology

Volumn 13, Issue 2, 2008, Pages 135-153

  Stevens, Larry E ^a   Missel, Paul J ^a   Weiner, Alan L ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

Controlled hydrodynamics; Extended release; Fully automated; High performance flow through dissolution; In vitro in vivo correlation

Indexed keywords

ANECORTAVE; ELIPRODIL; PACLITAXEL; POVIDONE;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; AUTOMATION; COMPUTER SIMULATION; CONTROLLED FLOW THROUGH DISSOLUTION SYSTEM; DRUG MANUFACTURE; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDRODYNAMICS; INSTRUMENTATION; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RABBIT; TABLET COMPRESSION;

ANIMALS; RABBITS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 41549088444     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450701831179     Document Type: Article

References (53)

1. Levy G. Effect of dissolution rate on absorption, metabolism and pharmacologic activity of drugs. J. Mond. Pharm. 1967;3:237-254.
2. Levy G. Effect of certain tablet formulation factors on dissolution rate of the active ingredient. J. Pharm. Sci. 1963;52:1039-1046.
3. Stevens LE, Missel PJ, Lang JC. Drug release profiles of ophthalmic formulations. 1. Instrumentation. Anal. Chem. 1992;64:715-723.
4. Missel PJ, Stevens LE, Mauger JW. Re-examination of convective diffusion/drug dissolution in a laminar flow channel: accurate prediction of dissolution rate. Pharm. Dev. Tech. 2004;21:2300-2306.
5. FIDAP 8.7.2, Using geometric meshes defined in GAMBIT 2.1.6 (Fluent, Inc., Lebanon, NH, USA).
6. Missel P, Stevens L, Chastain J, Yaacobi Y. Drug delivery to the eye. Fluent News 2006;XV(3):S8-10.
7. USP 28-NF 23. The United States Pharmacopeia-The National Formulary. Rockville, MD: United States Pharmacopeial Convention Inc.; 2005.
8. Cox DC, Wells EE, Furnam WB, Savage TS, King AC. Systematic error associated with apparatus 2 of the USP dissolution test. II: effects of deviations in vessel curvature from that of a sphere. J. Pharm. Sci. 1982;71:395-399.
9. Healy AM, McCarthy LG, Gallagher KM, Corrigan OI. Sensitivity of dissolution rate to location in the paddle dissolution apparatus. J. Pharm. Pharmacol. 2002;54:441-444.
10. Scott P. Geometric irregularities common to the dissolution vessel. Dis. Tech. 2005;12(1):18-21.
11. Crist B, Spisak D. Evaluation of induced variance of physical parameters on the calibrated USP dissolution apparatus 1 and 2. Dis. Tech. 2005;12(1):28-31.
12. Gray V. Challenges to the dissolution test, including equipment calibration. Dis. Tech. 2006;13(2):6-9.
13. McCarthy LG, Kosiol C, Healy AM, Bradley G, Sexton JC, Corrigan OI. Simulating the hydrodynamic conditions in the United States pharmacopeia paddle dissolution apparatus. AAPS Pharm. Sci. Tech. 2003;4(2):article 22.
14. McCarthy LG, Bradley G, Sexton JC, Corrigan OI, Healy AM. Computational fluid dynamics modeling of the paddle dissolution apparatus: Agitation rate, mixing patterns, and fluid velocities. AAPS Pharm. Sci. Tech. 2004;5(2):article 31.
15. Mirza T, Joshi Y, Liu Q, Vivilecchia R. Evaluation of dissolution hydrodynamics in the USP, Peek™ and flat-bottom vessels using different solubility drugs. Dis. Tech. 2005;12(1):11-16.
16. Fliszar KA, Forsyth RJ, Li Z, Martin GP. Effects of dissolved gases in surfactant dissolution media. Dis. Tech. 2005;12(3):6-11.
17. Kukura J, Baxter J, Muzzio F. Shear distribution and variability in the USP apparatus 2 under turbulent conditions. Int. J. Pharm. 2004;279:9-17.
18. Stevens LE, Missel PJ. Impact of density gradients on flow-through dissolution in a cylindrical flow cell. Pharm. Dev. Tech. 2006;11:529-534.
19. Missel PJ, Stevens LE. Adaptation of USP types II and IV dissolution assays for sparingly soluble compounds by direct eluent HPLC analysis. Pharm. Dev. Tech. 2006;11:87-91.
20. Zhang H, Xu L. Dissolution testing for solid oral drug products: theoretical considerations. Am. Pharm. Rev. 2004;7(5):26-31.
21. Siewert M, Dressman J, Brown C, Shah V. FIP/AAPS guidelines for dissolution/in vitro release testing of novel/special dosage forms. Diss. Tech. 2003;10:6-15.
22. Baun DC, Walker GC. Apparatus for determining the rate of drug release from solid dosage forms. J Pharm Sci. 1969;58(5):611-616.
23. Langenbucher F. In vitro assessment of dissolution kinetics: Description and evaluation of a column-type method. J Pharm Sci. 1969;58(10):1265- 1272.
24. Tingstad JE, Riegelman S. Dissolution rate studies I: Design and evaluation of a continuous flow apparatus. J Pharm Sci. 1970;59(5):692-696.
25. Langenbucher F, Rettig H. Dissolution rate testing with the column method: methodology and results. Drug. Dev. Ind. Pharm. 1977;3(3):241-262.
26. Langenbucher F, Benz D, Kurth W, Moller H, Otz M. Standardized flow-cell method as an alternative to existing pharmacopoeial dissolution testing. Pharm. Ind. 1989;51(11):1276-1281.
27. Kinel M, Meleh M, Veber M, Vrecer F. Study of physicochemical parameters affecting the release of diclofenac sodium from lipophilic matrix tablets. Acta Chim. Slov. 2004;51:409-425.
28. Hu J, Kyad A, Ku V, Zhou P, Cauchon N. A comparison of dissolution testing on lipid soft gelatin capsules using USP apparatus 2 and apparatus 4. Dis. Tech. 2005;12(2):6-10.
29. Beyssac E, Lavigne J. Dissolution study of active pharmaceutical ingredients using the flow through apparatus USP 4. Dis. Tech. 2005;12(2):23-27.
30. Derendorf H, Drehsen G, Rohdewald P. In vivo-in vitro correlations of salicylate saliva levels and continuous flow cell dissolutions rates. Int. J Pharm. 1983;15:167-175.
31. Phillips JG, Chen Y, Wakeling IN. A flow-through dissolution approach to in vivo/in vitro correlation of adinazolam release from substained. Drug Dev. Ind. Phar. 1989;15:2177-2195.
32. Emara LH, El-Menshawi BS, Estefan MY. In vitro-in vivo correlation and comparative bioavailability of vincamine in prolonged-release preparations. Drug Dev. Ind. Pharm. 2000;26(3):243-251.
33. Perng C-Y, Kearney AS, Palepu NR, Smith BR, Azzarano LM. Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens. Int. J. Pharm. 2003;250(1):147-156.
34. Fotaki N, Reppas C. The flow through cell methodology in the evaluation of intralumenal drug release characteristics. Dis. Tech. 2005;12(2):17-22.
35. Brown W. USP apparatus 4 flow through cell: Some thoughts on operational characteristics. Dis. Tech. 2005;12(2):28-32.
36. Frutos P, Pabon C, Lastres JL, Frutos G. In vitro release of metoclopramide from hydrophobic matrix tablets. Influence of hydrodynamic conditions of kinetic release parameter. Chem. Pharm. Bull. 2001;49(10):1267-1271.
37. Lerk CF, Zuurman, K. The influence of pulsation on the dissolution rate measurements in column type apparatus. J. Pharm. Pharmacol. 1970;22(4):319-320.
38. Hodson A, Wilkinson KA. Simultaneous sampling and HPLC injection from USP apparatus 4 using a dual sampling rack. Dis. Tech. 2005;12(2):44-45.
39. Thom K, Ziegler I. Development of an automated flow-through dissolution system for poorly soluble drugs with poor chemical stability in dissolution media. Pharmazie 1998;53(11):784-790.
40. Cakiryildiz C, Mehta PJ, Rahmen W, Shoenleber D. Dissolution studies with a multichannel continuous-flow apparatus. J Pharm Sci. 1975;64(10):1692-1697.
41. Zolnik BS, Raton J-L, Burgess DJ. Application of USP apparatus 4 and in situ fiber optic analysis to microsphere release testing. Dis. Tech. 2005;12(2):11-16.
42. Woodcock J. The concept of pharmaceutical quality. Am. Pharm. Rev. 2004;7(6):10-15.
43. Missel PJ, Stevens LE, Mauger JW. Dissolution of anecortave acetate in a cylindrical flow cell: re-evaluation of convective diffusion/drug dissolution for sparingly soluble drugs. Pharm. Dev. Tech. 2004;9:453-459.
44. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 1897;19:930-934.
45. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind. Eng. Chem. 1931;23:923-926.
46. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S. Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm. Res. 2006;23(6):1144-1156.
47. Nelson KG, Shah AC. Convective diffusion model for a transport-controlled dissolution rate process. J. Pharm Sci. 1975;64:610-614.
48. Shah AC, Nelson KG. Evaluation of a convective diffusion drug dissolution rate model. J. Pharm. Sci. 1975;64:1518-1520.
49. Mauger JW. Physicochemical and fluid mechanical factors related to dissolution testing. Dis. Tech. 1996;3(1):7-11.
50. Mauger JW, Howard SA, Khwangsopha A. Hydrodynamic characterization of a spin-filter dissolution device. J. Pharm. Sci. 1979;68(9):1084-1087.
51. Levich V. Physicochemical Hydrodynamics. Prentice Hall: New Jersey; 1962.
52. Schlichting H, Gersten K. Boundary Layer Theory. 8th ed. Berlin: Springer-Verlag; 2003.
53. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration (AMD): twelve-month clinical outcomes. Ophthalmology 2003;110(12):2372-2382.